ESMO Welcomes the Adoption of the 2017 WHO Cancer Resolution

Food and Healthcare Press Releases Friday June 2, 2017 09:02
LUGANO, Switzerland--2 Jun--PRNewswire/InfoQuest

ESMO, the leading European professional organisation for medical oncology, welcomes the adoption of the Resolution on Cancer prevention and control in the context of an integrated approach [http://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_ACONF9-en.pdf ]   during the 70th World Health Assembly (WHA), 22-31 May, Geneva, Switzerland.

ESMO President Fortunato Ciardiello said "ESMO welcomes the WHO resolution that aims to ensure access to safe, effective and affordable care for cancer patients. Sustainability of cancer care is one of the three pillars of the ESMO 2020 Vision. As medical oncologists treating cancer patients, we strongly advocate for equal access to quality treatment. Our support to the stakeholders involved in this landmark WHO Resolution is a clear sign of ESMO's pledge towards a world where cancer patients are taken care of by highly specialised professionals."

"The last WHO Cancer Resolution dates back to 2005 [http://www.who.int/ipcs/publications/wha/cancer_resolution.pdf?ua=1]. ESMO has been working with the WHO for many years to improve cancer care," Ciardiello added. "It is crucial that with the number of new cancer cases rising, and over 14 million new cases being diagnosed worldwide every year [http://www.who.int/mediacentre/factsheets/fs297/en], there is a global and joint effort not only to prevent cancer, but also to ensure that those affected by the disease get optimal treatment and care, wherever they live, whatever their economic conditions are."

The 2017 WHO Cancer Resolution calls for national cancer control plans, high quality cancer registries, increased cancer research, use of clinical practice guidelines, timely access to medicines, medical devices and palliative care, as well as a well-trained oncology workforce. "ESMO is active in all these areas and committed to providing quality information, resources and the best education for cancer professionals," stated Ciardiello.

Full story: http://bit.ly/2qxxbNH
ESMO Press Office
media@esmo.org
+41(0)91-973-19-07
Source: European Society for Medical Oncology (ESMO)

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics